View in EDS

Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.

Saved in:
Bibliographic Details
Title: Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
Authors: Robak, Tadeusz1 robaktad@csk.umed.lodz.pl, Jin, Jie2, Pylypenko, Halyna3, Verhoef, Gregor4, Siritanaratkul, Noppadol5, Drach, Johannes6, Raderer, Markus7, Mayer, Jiri8, Pereira, Juliana9, Tumyan, Gayane10, Okamoto, Rumiko11, Nakahara, Susumu12, Hu, Peter13, Appiani, Carlos13, Nemat, Sepideh14, Cavalli, Franco15, LYM-3002 investigators
Source: Lancet Oncology. Nov2018, Vol. 19 Issue 11, p1449-1458. 10p.
Database: Academic Search Ultimate
FullText Text:
  Availability: 0
Header DbId: asn
DbLabel: Academic Search Ultimate
An: 132754742
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Robak%2C+Tadeusz%22">Robak, Tadeusz</searchLink><relatesTo>1</relatesTo><i> robaktad@csk.umed.lodz.pl</i><br /><searchLink fieldCode="AR" term="%22Jin%2C+Jie%22">Jin, Jie</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Pylypenko%2C+Halyna%22">Pylypenko, Halyna</searchLink><relatesTo>3</relatesTo><br /><searchLink fieldCode="AR" term="%22Verhoef%2C+Gregor%22">Verhoef, Gregor</searchLink><relatesTo>4</relatesTo><br /><searchLink fieldCode="AR" term="%22Siritanaratkul%2C+Noppadol%22">Siritanaratkul, Noppadol</searchLink><relatesTo>5</relatesTo><br /><searchLink fieldCode="AR" term="%22Drach%2C+Johannes%22">Drach, Johannes</searchLink><relatesTo>6</relatesTo><br /><searchLink fieldCode="AR" term="%22Raderer%2C+Markus%22">Raderer, Markus</searchLink><relatesTo>7</relatesTo><br /><searchLink fieldCode="AR" term="%22Mayer%2C+Jiri%22">Mayer, Jiri</searchLink><relatesTo>8</relatesTo><br /><searchLink fieldCode="AR" term="%22Pereira%2C+Juliana%22">Pereira, Juliana</searchLink><relatesTo>9</relatesTo><br /><searchLink fieldCode="AR" term="%22Tumyan%2C+Gayane%22">Tumyan, Gayane</searchLink><relatesTo>10</relatesTo><br /><searchLink fieldCode="AR" term="%22Okamoto%2C+Rumiko%22">Okamoto, Rumiko</searchLink><relatesTo>11</relatesTo><br /><searchLink fieldCode="AR" term="%22Nakahara%2C+Susumu%22">Nakahara, Susumu</searchLink><relatesTo>12</relatesTo><br /><searchLink fieldCode="AR" term="%22Hu%2C+Peter%22">Hu, Peter</searchLink><relatesTo>13</relatesTo><br /><searchLink fieldCode="AR" term="%22Appiani%2C+Carlos%22">Appiani, Carlos</searchLink><relatesTo>13</relatesTo><br /><searchLink fieldCode="AR" term="%22Nemat%2C+Sepideh%22">Nemat, Sepideh</searchLink><relatesTo>14</relatesTo><br /><searchLink fieldCode="AR" term="%22Cavalli%2C+Franco%22">Cavalli, Franco</searchLink><relatesTo>15</relatesTo><br /><searchLink fieldCode="AR" term="%22LYM-3002+investigators%22">LYM-3002 investigators</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Lancet+Oncology%22">Lancet Oncology</searchLink>. Nov2018, Vol. 19 Issue 11, p1449-1458. 10p.
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=132754742
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S1470-2045(18)30685-5
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 10
        StartPage: 1449
    Titles:
      – TitleFull: Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Robak, Tadeusz
      – PersonEntity:
          Name:
            NameFull: Jin, Jie
      – PersonEntity:
          Name:
            NameFull: Pylypenko, Halyna
      – PersonEntity:
          Name:
            NameFull: Verhoef, Gregor
      – PersonEntity:
          Name:
            NameFull: Siritanaratkul, Noppadol
      – PersonEntity:
          Name:
            NameFull: Drach, Johannes
      – PersonEntity:
          Name:
            NameFull: Raderer, Markus
      – PersonEntity:
          Name:
            NameFull: Mayer, Jiri
      – PersonEntity:
          Name:
            NameFull: Pereira, Juliana
      – PersonEntity:
          Name:
            NameFull: Tumyan, Gayane
      – PersonEntity:
          Name:
            NameFull: Okamoto, Rumiko
      – PersonEntity:
          Name:
            NameFull: Nakahara, Susumu
      – PersonEntity:
          Name:
            NameFull: Hu, Peter
      – PersonEntity:
          Name:
            NameFull: Appiani, Carlos
      – PersonEntity:
          Name:
            NameFull: Nemat, Sepideh
      – PersonEntity:
          Name:
            NameFull: Cavalli, Franco
      – PersonEntity:
          Name:
            NameFull: LYM-3002 investigators
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 11
              Text: Nov2018
              Type: published
              Y: 2018
          Identifiers:
            – Type: issn-print
              Value: 14702045
          Numbering:
            – Type: volume
              Value: 19
            – Type: issue
              Value: 11
          Titles:
            – TitleFull: Lancet Oncology
              Type: main
ResultId 1